These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2219608)

  • 21. [Prevention of urinary calculi with covalitin and by general measures].
    Bianchi F
    Helv Chir Acta; 1978 Jul; 45(3):261-2. PubMed ID: 701061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allopurinol in the recurrence prevention of calcium oxalate lithiasis.
    Brien G; Bick C
    Eur Urol; 1977; 3(1):35-6. PubMed ID: 837952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes.
    Mandel N; Mandel I; Fryjoff K; Rejniak T; Mandel G
    J Urol; 2003 Jun; 169(6):2026-9. PubMed ID: 12771710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renal electrolyte changes by allopurinol. A contribution in the prophylaxis of oxalic acid stones (author's transl)].
    Garke P; Terhorst B
    Urologe A; 1974 Jul; 13(4 Pt A):166-7. PubMed ID: 4212796
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacologic treatment of uric acid calculi.
    Preminger GM
    Urol Clin North Am; 1987 May; 14(2):335-8. PubMed ID: 3576854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug dosage protocol for calcium oxalate stone.
    Marickar YM; Salim A
    Urol Res; 2009 Dec; 37(6):353-7. PubMed ID: 19826800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the discriminant index in dynamic treatment to reduce recurrence of calcium oxalate kidney stones.
    Perlberg S; Azoury R; Garti N; Sarig S
    Br J Urol; 1985 Oct; 57(5):500-4. PubMed ID: 2998532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of effect of allopurinol on oxalate excretion by stone patients on random and controlled diets.
    Urivetzky M; Braverman S; Motola JA; Smith AD
    J Urol; 1990 Jul; 144(1):97-8. PubMed ID: 2359187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urolithiasis in geriatric patients.
    Usui Y; Matsuzaki S; Matsushita K; Shima M
    Tokai J Exp Clin Med; 2003 Jul; 28(2):81-7. PubMed ID: 14714833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of recurrent uric acid and calcium oxalate stones by administration of the xanthine oxidase inhibitors Milurit 100 and Milurit 300.
    Schneider HJ; Brundig P; Balogh A; Traeger A; Stein G; Fünfstück R
    Int Urol Nephrol; 1983; 15(2):121-9. PubMed ID: 6688800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allopurinol for stones: right drug--wrong reasons.
    Grover PK; Ryall RL
    Am J Med; 2007 May; 120(5):380. PubMed ID: 17466643
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of calcium nephrolithiasis in the patient with hyperuricosuria.
    Arowojolu O; Goldfarb DS
    J Nephrol; 2014 Dec; 27(6):601-5. PubMed ID: 24687403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical results of allopurinol treatment in prevention of calcium oxalate stone formation.
    Tiselius HG; Larsson L; Hellgren E
    J Urol; 1986 Jul; 136(1):50-3. PubMed ID: 3712614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allopurinol treatment of renal calcium stone disease.
    Fellström B; Backman U; Danielson BG; Holmgren K; Johansson G; Lindsjö M; Ljunghall S; Wikström B
    Br J Urol; 1985 Aug; 57(4):375-9. PubMed ID: 4027505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alkali citrate for preventing recurrence of calcium oxalate stones.
    Hauser W; Frick J; Kunit G
    Eur Urol; 1990; 17(3):248-51. PubMed ID: 2190842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trace elements in urinary stones: a preliminary investigation in Fars province, Iran.
    Keshavarzi B; Yavarashayeri N; Irani D; Moore F; Zarasvandi A; Salari M
    Environ Geochem Health; 2015 Apr; 37(2):377-89. PubMed ID: 25433503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial.
    Soygür T; Akbay A; Küpeli S
    J Endourol; 2002 Apr; 16(3):149-52. PubMed ID: 12028622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gouty diathesis and sarcoidosis in patient with recurrent calcium nephrolithiasis.
    Harvey JA; Pak CY
    J Urol; 1988 Jun; 139(6):1287-9. PubMed ID: 3373603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate?
    Tiselius HG
    Urolithiasis; 2015 Jan; 43 Suppl 1():47-57. PubMed ID: 25086904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.